Afinitor

What Afinitor is used for

Hormone-receptor-positive advanced breast cancer Afinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor. Neuroendocrine tumours of pancreatic origin Afinitor is indicated for the treatment of unresectable or metastatic, well or moderately differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease. Neuroendocrine tumours of gastrointestinal or lung origin Afinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. Renal-cell carcinoma Afinitor is indicated for the treatment of patients with advanced renal-cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.

Approved use, as published by the European Medicines Agency.

Key facts

Brand

Afinitor

Active substance

everolimus

Disease area

Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms

Medicine group

Antineoplastic agents

ATC code

L01XE10

Marketing authorisation holder

Novartis Europharm Limited

Authorised in the EU since

2009

Official information

• Afinitor: European public assessment report (EPAR), product information and package leaflet, on the EMA website

In the USA

Same active substance: Afinitor Disperz, Zortress, Afinitor

In India

• Everolimus: 34 brands in India